Last reviewed · How we verify
NCT05951426
Expression Analysis of the COPB 2 and Bcl-2 in Early Stages of Endometrial Carcinoma
trial testing 1.hysterectomy with bilateral oophorectomy and pelvic lymphonodectomy. 2 explorative curettage in Endometrial Carcinoma Cellular Diagnosis in 60 participants. Completed in 1 October 2022.
21 December 2021
Quick facts
| Lead sponsor | Clinical Center Kragujevac |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 17 April 2019 |
| Primary completion | 21 December 2021 |
| Estimated completion | 1 October 2022 |
Drugs / interventions tested
- 1.hysterectomy with bilateral oophorectomy and pelvic lymphonodectomy. 2 explorative curettage
Conditions studied
- Endometrial Carcinoma Cellular Diagnosis — all drugs for Endometrial Carcinoma Cellular Diagnosis →
Sponsor
Clinical Center Kragujevac
Who can join
Eligibility, female only, with Endometrial Carcinoma Cellular Diagnosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
COPB2 is a subunit of the intracellular transport system between cell organelles that participates in the regulation of cell division and differentiation. Bcl-2 is a protein that participates in regulating the process of apoptosis. Through the research,investigators tried to examine and establish the correlation of the expression of these two genes in endometrial cancer at an early stage.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05951426
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05951426 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Clinical Center Kragujevac
- Last refreshed: 19 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05951426.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing